Status:
COMPLETED
Application of Telemedicine to the Management of Aggressive Lymphomas
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Lymphoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the value of AMA in a comparative multicenter regional study as a reference for aggressive lymphoma. The primary endpoint will be RDI. This study consider that...
Eligibility Criteria
Inclusion
- Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven, with treatment not started
- a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP).
- Index international prognosis (IPI) measurable (IPI-aa), adjusted for age. Any IPI-aa is eligible.
- accepting the study
Exclusion
- Patient with another type of lymphoma (including transformed follicular forms)
- Patient having already started his treatment.
- Life expectancy \<3 months.
- Carcinologic history
- Serum positive for HIV or hepatitis B virus (HBV).
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2019
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT03336138
Start Date
January 1 2012
End Date
January 31 2019
Last Update
December 15 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Toulouse
Toulouse, France, France
2
Clinique Claude Bernard
Albi, France, 81000
3
Hospital
Auch, France, 32000
4
Bayonne Hospital
Bayonne, France, 64000